Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5755293 | 0.86 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL4705199 | 0.86 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL6052826 | 0.84 | GRIN2B (0.35) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL4437296 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL3000663 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL10039817 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL692636 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL3000664 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL4309286 | 0.80 | GRIN2B (0.40) | GRIN2BGRIN2CEPHX2JAK3USP2 | |
| SCHEMBL15936853 | 0.79 | GRIN2B (0.38) | GRIN2BGRIN2CEPHX2JAK3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | GRIN2B 3538/4885GRIN2C 3426/4885EPHX2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.